Slaughter R L, Hassett J M
Drug Intell Clin Pharm. 1985 Nov;19(11):799-806. doi: 10.1177/106002808501901101.
Trauma is a complex disease state associated with physiologic changes that have the potential to alter hepatic drug clearance mechanisms. These responses include alterations in hepatic blood flow, reduction in hepatic microsomal activity, reduction in hepatic excretion processes, and changes in protein binding. Hepatic blood flow is influenced by sympathomimetic activity. Both animal and human studies demonstrate an initial reduction and subsequent increase in hepatic blood flow, which coincides with an observed increase and subsequent return to normal in serum catecholamine concentrations. Unfortunately, there are no human studies that address the importance these findings may have to the clearance processes of high intrinsic clearance compounds. Animal studies of trauma indicate that hepatic microsomal activity is depressed during the post-traumatic period. Reduction in the hepatic clearance of antipyrine, a model low intrinsic compound, has also been demonstrated in animal models of trauma. In addition to these effects, hepatic excretion of substances such as indocyanine green and bilirubin have been demonstrated to be impaired in both traumatized animals and humans. Finally, substantial increases in the serum concentration of the binding protein alpha 1-acid glycoprotein occur in trauma patients. This has been reported to be associated with subsequent decreases in the free fraction of lidocaine and quinidine. In addition to changing serum drug concentration/response relationships, the pharmacokinetic behavior of drugs bound to alpha 1-acid glycoprotein should also change. Preliminary observations in our laboratory in a dog model of surgically-induced trauma have shown a reduction in the total clearance of lidocaine and reduction in free lidocaine concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
创伤是一种复杂的疾病状态,与可能改变肝脏药物清除机制的生理变化相关。这些反应包括肝血流量改变、肝微粒体活性降低、肝脏排泄过程减少以及蛋白结合变化。肝血流量受拟交感神经活性影响。动物和人体研究均表明,肝血流量最初会减少,随后增加,这与血清儿茶酚胺浓度先升高随后恢复正常的情况相符。遗憾的是,尚无人体研究探讨这些发现对于高内在清除率化合物清除过程的重要性。创伤的动物研究表明,创伤后时期肝微粒体活性会受到抑制。在创伤动物模型中也已证实,作为低内在清除率模型化合物的安替比林的肝脏清除率降低。除了这些影响外,在创伤动物和人体中均已证实,吲哚菁绿和胆红素等物质的肝脏排泄受损。最后,创伤患者血清中结合蛋白α1-酸性糖蛋白的浓度会大幅升高。据报道,这与利多卡因和奎尼丁的游离分数随后降低有关。除了改变血清药物浓度/反应关系外,与α1-酸性糖蛋白结合的药物的药代动力学行为也应会发生变化。我们实验室在手术诱导创伤犬模型中的初步观察表明,利多卡因的总清除率降低,游离利多卡因浓度降低。(摘要截选至250词)